Public trial registry of the CCC-Munich

Trial RELAZA2

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
RELAZA2
World
Full title
:

Behandlung des drohenden hämatologischen
Rezidivs von Patienten mit MDS oder AML
mit Azacitidin (Vidaza )

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Medizinische Klinik III, Telefon: 089440072551
Indications
Classification Code Description
ICD-10-GM C92.0- Akute myeloblastische Leukämie [AML]
- Bloodcancer (leukemia, lymphoma)
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
II
Status
World
Status
:
Trial finished
Votes
World
Institutional review board - vote
:
Unknown
World
Institutional review board - vote date
:
EK 23306
Initiiation & lock
World
Date of lock (planned / actual)
:
2021-02-28 / Unknown
Participants
Function Prename Surname Organization
World Principal Investigator Karsten Spiekermann Keine Organisationseinheit angegeben Magnifier
World Responsible contact Valeria Besik Keine Organisationseinheit angegeben Magnifier